A significant difference between the TRPM7 agonist (20 IU/mL IL-2 + 25 μM NTB) and TRPM7 antagonist (20 IU/mL IL-2 + 25 μM NTB + 10 μM NS8593) treatments was observed within the HC cohort (p < 0.01) and ME/CFS cohort (p < 0.05) specifically showing an increase in TRPM7 co-localization with PIP2 with TRPM7 antagonism (Figure 5). This evidence concerns the gene IL2 and myalgic encephalomeyelitis/chronic fatigue syndrome.